Frontlight ResearchEarly access
CompletedPhase 1
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Key facts
- Who runs it
- Azitra Inc.
- Where
- New Haven and Palo Alto, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 6 people enrolled
- Started
- 16 Jun 2024
- Ended
- 7 Jul 2026
- Type of study
- Interventional
- Treatments tested
- ATR12-351
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults ≥18 years of age
- Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene
- Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome
Who cannot take part
- Concurrent involvement in any other clinical study/expanded access program with an investigational drug or device or has participated in a clinical study within 30 days prior to the screening visit
- History of ultraviolet phototherapy within the planned treatment area 4 weeks prior to baseline
- Use of biologic therapies, antibiotics, antihistamines, corticosteroids, retinoids, disease-modifying antirheumatic drugs (DMARDs), immunosuppressive agents, phosphodiesterase-4 (PDE4) inhibitors, topical calcineurin inhibitors, or topical Janus kinase (JAK) inhibitors
- Open wounds or extensive areas of excoriation precluding identification of appropriate application sites in the Investigator's judgment
- Residing with an immunocompromised person in the same dwelling from the baseline visit through 2 weeks after the treatment period
Where in United States
- Yale UniversityNew Haven, United States
- Stanford UniversityPalo Alto, United States
About the trial
What the trial wants to find out
The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.
The group in the trial
- Internal controlled armTreatment being tested
ATR12-351 on left side of body, vehicle on right side of body in one group; vehicle on left side of body, ATR12-351 on right side of body.
Treatment: ATR12-351
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome
- Record updated
- 29 July 2026